LL-37 and Inflammatory Skin Disease: The Double-Edged Side of an Antimicrobial Peptide

LL-37 is usually introduced as a friendly molecule: a natural antimicrobial peptide that helps the body defend itself. That framing is accurate, but incomplete. The same peptide is also a recurring character in the research literature on inflammatory skin disease, where too much LL-37, or LL-37 cut into the wrong fragments, appears to drive inflammation rather than calm it. This is the part of LL-37 biology that marketing rarely mentions.

Understanding this double edge is the most useful thing a careful reader can take from the LL-37 literature. It explains why "boost your antimicrobial peptides" is a confused goal, and why dermatology researchers spend as much effort trying to reduce LL-37 activity in some conditions as they do studying its defensive value in others.

For molecule background, start with the LL-37 peptide guide. For the wound and infection question specifically, see our LL-37 wound-healing and infection evidence review. This page focuses on a different question: how the same host-defense peptide becomes a suspect in rosacea, psoriasis, and other inflammatory skin conditions, and what that means for the claims you read.

A Defense Molecule With Two Faces

LL-37 is genuinely part of innate immunity. It can disrupt microbial membranes and it participates in signaling that recruits immune cells, supports barrier repair, and influences wound biology. But "active in immunity" is not the same as "calming" or "anti-inflammatory." A review of LL-37 in inflammatory skin disease describes it as a peptide whose effects depend heavily on context: concentration, which fragments are present, where it is, and what other signals surround it.

That context-dependence is why the same molecule shows up on both sides of the ledger. In a clean defensive role it helps clear microbes. In a dysregulated state it can amplify inflammation, recruit immune cells inappropriately, and even help convert the body's own DNA into an alarm signal. Both behaviors are real and both are documented in peer-reviewed research. Largely, this remains research-stage biology, with limited human therapeutic data and no FDA-approved consumer LL-37 product.

What LL-37 Actually Is

LL-37 is the mature 37-amino-acid peptide released from the human cathelicidin precursor protein encoded by the CAMP gene, which NCBI Gene lists as the cathelicidin antimicrobial peptide gene. The precursor is stored in an inactive form and must be cut by enzymes to release active peptides. Which enzyme does the cutting, and how, determines which fragments appear, and those fragments are not biologically equivalent.

This processing step is the crux of the inflammatory-disease story. In healthy skin, the cathelicidin fragments tend to be the forms associated with quiet defense. In some disease states, abnormal processing yields different fragments with stronger pro-inflammatory and blood-vessel-stimulating activity. The peptide sequence is human, but the version your skin generates depends on the enzymatic environment.

Rosacea: When Processing Goes Wrong

Rosacea is the clearest example of LL-37 as a driver rather than a helper. A landmark 2007 Nature Medicine study by Yamasaki and colleagues reported that facial skin in rosacea contains abnormally high levels of cathelicidin, and that the processed fragments differ from those in normal skin. They linked this to increased activity of the serine protease kallikrein 5 (also called stratum corneum tryptic enzyme), which cleaves the cathelicidin precursor.

The consequence is a cascade. More kallikrein 5 activity means more LL-37 and more of its inflammatory fragments. Those peptides promote innate cutaneous inflammation, vasodilation, and vascular proliferation, features that map closely onto the redness, flushing, and visible vessels of rosacea. The researchers also reported that injecting these rosacea-associated peptide fragments into mouse skin produced rosacea-like changes, which points to a causal role rather than a coincidental one.

This reframes part of rosacea as a disorder of innate immunity and abnormal peptide processing. It also reframes several existing treatments. Reviews note that agents used in rosacea, including azelaic acid and certain anti-inflammatory approaches, are associated with reduced cathelicidin and kallikrein 5 activity. In rosacea, the therapeutic direction researchers pursue is generally toward less LL-37 activity, not more.

Psoriasis: LL-37 As An Autoantigen

Psoriasis tells an even more pointed story. LL-37 is overexpressed in psoriatic skin, and research suggests it does something unusual: it binds fragments of the body's own DNA and RNA released from dying cells, forming complexes that plasmacytoid dendritic cells then sense through pattern-recognition receptors such as TLR9. This triggers type I interferon release and helps ignite an inflammatory cascade, a process proposed as an early event in psoriasis.

A 2014 Nature Communications study went further and identified LL-37 itself as a T-cell autoantigen in psoriasis. The authors reported that roughly two-thirds of patients with moderate-to-severe plaque psoriasis had circulating T cells that recognized LL-37, meaning the immune system was treating an endogenous defense peptide as a target. Related work shows LL-37 can also prime keratinocytes to react against TLR9 ligands, amplifying the loop.

This is a sharp contrast with the "immune support" framing. Here the same peptide marketed as a wellness booster is implicated in self-directed, autoimmune-flavored inflammation. The broader immunomodulation literature extends similar concerns to discussions of lupus and other autoimmune contexts, which is exactly why casual systemic-LL-37 claims deserve skepticism.

Atopic Dermatitis: The Opposite Problem

Atopic dermatitis (eczema) flips the picture again, which is why a one-line story about LL-37 fails. Lesional atopic skin tends to show lower cathelicidin and LL-37 levels than psoriatic skin. Researchers have proposed that this relative deficiency, driven in part by the IL-4 and IL-13 signaling abundant in atopic skin, contributes to the increased susceptibility to skin infections, including Staphylococcus aureus, that characterizes the condition.

So across three common conditions, LL-37 is too active in rosacea, abnormally weaponized in psoriasis, and relatively scarce in atopic dermatitis. There is no single direction that "more LL-37" or "less LL-37" is universally good. The right amount, in the right form, in the right place is the entire point, and none of that is something a consumer product can meaningfully tune.

How To Read LL-37 Claims After This

This biology gives readers a practical filter. When a product or article describes LL-37 as a simple immune booster or anti-inflammatory peptide, it is ignoring a large body of dermatology research in which LL-37 contributes to inflammation and even autoimmunity. LL-37 is context-dependent, not uniformly beneficial.

• Be skeptical of "anti-inflammatory peptide" framing. In rosacea and psoriasis, LL-37 activity is part of the problem researchers try to reduce.
• Treat "boosts immunity" as marketing, not biology. The peptide can act as a self-antigen and amplify type I interferon responses in disease states.
• Remember that fragment identity matters. Abnormal cathelicidin processing, not just total amount, drives rosacea-associated inflammation.
• Note the regulatory context. FDA's compounding-risk materials list cathelicidin LL-37 among substances that may present significant safety risks, citing immunogenicity and characterization concerns.
• Recognize the evidence stage. Most of this is mechanistic and preclinical; human therapeutic data for LL-37 outside narrow topical wound research remain limited.

For a broader framework on separating mechanism from outcome, see How to Read a Peptide Study. The same discipline applies here: a documented mechanism, even a fascinating one, is a reason to study a molecule carefully, not a license to sell it as a self-administered immune product.

FAQ

Is LL-37 anti-inflammatory or pro-inflammatory? Both, depending on context. It supports defense in some settings but contributes to inflammation in rosacea and psoriasis. There is no single answer that fits every tissue and condition.

Does LL-37 cause rosacea? Research strongly implicates abnormal cathelicidin processing and elevated LL-37 fragments in rosacea inflammation, including a mouse model where injected fragments produced rosacea-like changes. It is described as a contributor in the disease cascade, not a proven sole cause in people.

Why is LL-37 called an autoantigen in psoriasis? Because a 2014 study found that many psoriasis patients have T cells that recognize LL-37 as a target, and LL-37 also helps the immune system react to the body's own DNA. That is the opposite of a simple protective role.

Should people with skin conditions use LL-37 products? This article does not give medical advice. Given that LL-37 is implicated in several inflammatory skin diseases and flagged in FDA compounding-risk materials, anyone with a skin or immune condition should rely on qualified clinicians, not peptide products.

References

• Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea, Nature Medicine / Yamasaki et al., 2007.
• Cathelicidin LL-37: An Antimicrobial Peptide with a Role in Inflammatory Skin Disease, Dermato-Endocrinology / PubMed.
• Rosacea as a Disease of Cathelicidins and Skin Innate Immunity, Journal of Investigative Dermatology Symposium Proceedings.
• Kallikrein 5-Mediated Inflammation in Rosacea: Clinically Relevant Correlations with Acute and Chronic Manifestations, Journal of Clinical and Aesthetic Dermatology / PMC.
• The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis, Nature Communications / Lande et al., 2014.
• Cathelicidin Antimicrobial Peptide LL-37 in Psoriasis Enables Keratinocyte Reactivity against TLR9 Ligands, Journal of Investigative Dermatology / PMC.
• Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections, Vaccines (Basel) / PMC.
• CAMP cathelicidin antimicrobial peptide [Homo sapiens], NCBI Gene.
• Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, U.S. Food and Drug Administration.

Disclaimer

This page is educational and is not medical advice. It does not provide dosing, topical-use, injection, reconstitution, compounding, sourcing, purchasing, or storage instructions for LL-37. Rosacea, psoriasis, atopic dermatitis, other inflammatory or autoimmune skin disease, suspected infection, and peptide-product questions should be handled with qualified healthcare professionals and current regulator-reviewed information.